This is a prospective open enrollment registry to evaluate arterial blood and thrombus removed during the standard thrombectomy procedure, which will then be used for the purposes of identifying biological markers, inflammatory cell infiltrates, and biological states in large vessel occlusive stroke in the human condition. The primary objectives are to evaluate the feasibility of obtaining distal clot blood during thrombectomy; develop a group of biosamples (blood and clots) to evaluate novel proteins, cell types, and cytokines in acute ischemic stroke in the human condition, and evaluate specific biomarkers, proteins, and leukocyte populations in stroke in the human condition. The study population will include up to 250 subjects. Male and female participants 18 years of age and older will be enrolled. Participants must have had a suspected acute ischemic stroke based on clinical and radiographic evidence as determined and documented by the Stroke Neurology team at University of Kentucky. There is no therapeutic intervention involved in this study.
This is the first study to our knowledge that will utilize thrombectomy technique to collect focal blood samples and the clot related brain infarction. This proposal will provide preliminary data needed to understand relationships between the local inflammatory cascade and clinical variables such as age, gender, time from symptoms to thrombectomy, and stroke imaging results. Characterizing these relationships is vital in the formulation of related therapeutics. Issues of gender-differences, age-based variations, and co-morbidities all engender heterogeneity, which plague translation of stroke research from animal to human. By starting with the human condition, the investigators aim to minimize this loss in translation. Overall, this study will have a great impact on our knowledge of stroke pathology. In essence, this could fundamentally change not only how the investigators develop treatment strategies for the stroke patient population but allow us to individualize the treatment dependent on time after stroke, age, sex, and co-morbidities. Molecular techniques that are impractical when delivered systemically could be delivered locally to impede the early inflammation.
This study represents the first time that clot and blood will be evaluated for the markers, proteins, and cytokines listed in the protocol in human subjects undergoing thrombectomy for emergent large vessel occlusion stroke. The study is an open, unblinded, clinical and biologic registry to evaluate specific questions that are novel to understanding stroke in the human condition. There is no therapeutic intervention involved in this study. The study population will include up to 250 subjects enrolled at the University of Kentucky. The primary endpoints of the study will be evaluation of specific proteins and leukocyte populations in the human stroke clot and blood. Secondary endpoints include: Acid/Base Balance: Evaluate pH of blood as a marker of acid/base balance in distal blood and proximal blood, and correlate to interval of time between Last Known Normal and vessel recanalization; Inpatient Biomarker; Protein, RNA, expression with Clinical Correlation.
Participants will be recruited from patients evaluated at University of Kentucky Chandler Hospital for acute ischemic stroke. Participants with impaired capacity may be included as the pathology to be studied (stroke) may impair their capacity.
The study events occur during the acute hospitalization for the subject's condition (acute ischemic stroke).
Baseline (Day 0):
Datapoints recorded will include the vessel location of the thrombus and time from Last Known Normal to vessel recanalization, along with TICI (Thrombolysis in Cerebral Infarction) score.
Study Specimen Collection
All endpoints listed below are standard of care for followup after thrombectomy.
The following clinical endpoints will be captured:
Visit 1 (Within 48 hours)
MRI or CT is performed typically within 48 hours after thrombectomy as standard of care. Radiographic endpoints that will be captured include:
For the purposes of this study, the central clinical endpoint will be time from Last Known Normal to thrombectomy completion. The other data points will be captured for exploratory purposes as correlations and associations with immune cell and cytokine levels may lead to future studies beyond the scope of this grant.
Visit 2 (By and At Discharge) Data collection by Discharge: discharge destination; NIHSS; Mini-Montreal Cognitive Assessment (MiniMoCA) or similar cognitive scale outcome variables. (Standard of Care) Data collection at Discharge: mRS. (Standard of Care)
Visit 3 (90 Day Standard of Care Follow-Up) Data Collection: mRS and Montreal Cognitive Assessment (MoCA). (Standard of Care)
Laboratory Procedures/Evaluations The three biospecimen samples described will be banked, and may be used for pH analysis and electrolyte analysis, serum biomarker analysis, protein and RNA levels, and leukocyte populations. These analyses may be correlated to clinical factors including but not limited to age/gender, interval from Last Known Normal, location of the thrombus, medical co-morbidities, and source of the thrombus.
Condition | Acute Ischemic Stroke |
---|---|
Treatment | Registry |
Clinical Study Identifier | NCT03153683 |
Sponsor | Justin Fraser |
Last Modified on | 19 June 2022 |
,
You have contacted , on
Your message has been sent to the study team at ,
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreEvery year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.